IDEXX Laboratories, Inc. $IDXX Shares Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 67.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 287,937 shares of the company’s stock after acquiring an additional 115,698 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.36% of IDEXX Laboratories worth $161,763,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. SHP Wealth Management purchased a new stake in IDEXX Laboratories during the fourth quarter worth approximately $26,000. Virtus Advisers LLC purchased a new position in IDEXX Laboratories in the third quarter valued at approximately $26,000. Park Place Capital Corp acquired a new stake in IDEXX Laboratories during the fourth quarter worth approximately $29,000. WealthCollab LLC acquired a new stake in IDEXX Laboratories during the second quarter worth approximately $30,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter worth approximately $36,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX stock opened at $551.50 on Monday. The company has a fifty day moving average price of $558.79 and a 200 day moving average price of $614.13. IDEXX Laboratories, Inc. has a 12 month low of $506.91 and a 12 month high of $769.98. The company has a market cap of $43.50 billion, a price-to-earnings ratio of 40.61, a price-to-earnings-growth ratio of 3.02 and a beta of 1.56. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the prior year, the business earned $2.91 EPS. IDEXX Laboratories’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

IDXX has been the subject of several research analyst reports. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. UBS Group reduced their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Finally, Citigroup started coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.